Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 1/2020

01-01-2020 | Laparoscopy | Research Article

Two-dimensional versus three-dimensional laparoscopic gastrectomy in surgical efficacy for gastric cancer: a systematic review and meta-analysis

Authors: G. Zu, K. Jiang, T. Zhou, N. Che, X. Zhang

Published in: Clinical and Translational Oncology | Issue 1/2020

Login to get access

Abstract

Background

The surgical efficacy of three-dimensional (3D) and two-dimensional (2D) laparoscopic gastrectomy for gastric cancer remains controversial. A meta-analysis with all eligible studies was conducted to explore the surgical efficacy of 2D versus 3D laparoscopic gastrectomy for gastric cancer.

Methods

A systematic search was performed. The weighted mean difference (WMD) or odds risk (OR) of patients with 2D or 3D laparoscopic gastrectomy were used to calculate surgical efficacy of 3D and 2D laparoscopic gastrectomy for gastric cancer.

Results

Ten studies involving 1478 patients who underwent 2D or 3D laparoscopic gastrectomy were identified. Three-dimensional laparoscopic gastrectomy decreases operation time (WMD: − 16.517, 95% CI − 25.550 to − 7.484, P = 0.000), intraoperative blood loss (WMD: − 21.060, 95% CI − 32.209 to − 9.911, P = 0.000) and number of retrieved lymph nodes (WMD: 3.699, 95% CI 1.838–5.560, P = 0.000) compared with 2D laparoscopic surgery. However, no differences in time to first postoperative flatus (WMD: − 0.119, 95% CI − 0.330 to − 0.092, P = 0.269), perioperative complications (OR: 0.901, 95% CI 0.649–1.251, P = 0.534), or hospital stay (WMD: − 0.624, 95% CI − 1.983 to 0.735, P = 0.368) were noted between 3D and 2D laparoscopic gastrectomy for gastric cancer.

Conclusion

3D laparoscopic gastrectomy decreases the operation time, intraoperative blood loss, and numbers of retrieved lymph nodes compared with 2D laparoscopic gastrectomy for gastric cancer.
Literature
1.
Moraga-Serrano PE. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–68.CrossRef
2.
Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/world congress on gastrointestinal cancer, Barcelona, 2010. Ann Oncol. 2011;22(suppl 5):v1–9.CrossRef
3.
Hu Y, Ying M, Huang C, Wei H, Jiang Z, Peng X, et al. Oncologic outcomes of laparoscopy-assisted gastrectomy for advanced gastric cancer: a large-scale multicenter retrospective cohort study from China. Surg Endosc. 2014;28:2048–56.CrossRef
4.
Lin JX, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Laparoscopy-assisted gastrectomy with D2 lymph node dissection for advanced gastric cancer without serosa invasion: a matched cohort study from South China. World J Surg Oncol. 2013;11:4.CrossRef
5.
Lee JH, Nam BH, Ryu KW, Ryu SY, Park YK, Kim S, et al. Comparison of outcomes after laparoscopy-assisted and open total gastrectomy for early gastric cancer. Br J Surg. 2015;102(12):1500–5.CrossRef
6.
Yamashita K, Sakuramoto S, Kikuchi S, Futawatari N, Katada N, Hosoda K, et al. Laparoscopic versus open distal gastrectomy for early gastric cancer in Japan: long-term clinical outcomes of a randomized clinical trial. Surg Today. 2015;46:741–9.CrossRef
7.
Ben-David K, Tuttle R, Kukar M, Oxenberg J, Hochwald SN. Laparoscopic distal, subtotal gastrectomy for advanced gastric cancer. J Gastrointest Surg. 2015;19:369–74.CrossRef
8.
Hamabe A, Omori T, Tanaka K, Nishida T. Comparison of long-term results between laparoscopy-assisted gastrectomy and open gastrectomy with D2 lymph node dissection for advanced gastric cancer. Surg Endosc. 2012;26:1702–9.CrossRef
9.
Park YK, Yoon HM, Kim YW, Park JY, Ryu KW, Lee YJ, et al. Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: results from a randomized phase II Multicenter Clinical Trial (COACT 1001). Ann Surg. 2018;267(4):638–45.CrossRef
10.
Kanaji S, Suzuki S, Harada H, Nishi M, Yamamoto M, Matsuda T, et al. Comparison of two- and three-dimensional display for performance of laparoscopic total gastrectomy for gastric cancer. Langenbecks Arch Surg. 2017;402(3):493–500.CrossRef
11.
Zheng CH, Lu J, Zheng HL, Li P, Xie JW, Wang JB, et al. Comparison of 3D laparoscopic gastrectomy with a 2D procedure for gastric cancer: a phase 3 randomized controlled trial. Surgery. 2018;163(2):300–4.CrossRef
12.
Ji G, Qi S, Ji F, Tao Y, Ma C, Fang X. Comparative study of three-dimensional and two-dimensional laparoscopic-assisted D2 radical gastrectomy in short-term efficacy. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19(5):545–8.PubMed
13.
Liu J, Zhou H, Qin H, Ru H, Huang J, Liang S, et al. Comparative study of clinical efficacy using three-dimensional and two-dimensional laparoscopies in the treatment of distal gastric cancer. Onco Targets Ther. 2018;11:301–6.CrossRef
14.
Lu J, Zheng CH, Zheng HL, Li P, Xie JW, Wang JB, et al. Randomized, controlled trial comparing clinical outcomes of 3D and 2D laparoscopic surgery for gastric cancer: an interim report. Surg Endosc. 2017;31(7):2939–45.CrossRef
15.
Zh Y. Comparative analysis of therapeutic effects of 3D and 2D laparoscopic radical gastrectomy for gastric cancer. Fujian Med J. 2018;40(3):98–100.
16.
Li S, Song L, Na X, Zhang H, Li Y, Hu Z, et al. A comparison of 3D and 2D assisted Roux-en-Y anastomosis of laparoscopic distal gastrectomy for gastric cancer. Chin J Laparosc Surg (Electronic Edition). 2017;10(3):136–8.
17.
Ji F, Fang X, Fei B. Comparative study of 3D and 2D laparoscopic surgery for gastrointestinal tumors. Chin J Gastrointest Surg. 2017;20(5):509–13.
18.
Wang J, Xing J, Liu H, Fu H, Kang J. Comparative study of 3D and 2D laparoscopic distal gastrectomy for patients with gastric cancer. Chin J Oper Proc Gen Surg (Electronic Edition). 2018;12(2):115–8.
19.
Zheng Y, Li W, Wang H, Lin Y. Comparative study of short term clinical efficacy of 3D and 2D laparoscopic radical resection of gastric cancer. J Dig Oncol (Electronic Edition). 2017;9(1):31–4.
20.
Yu Y, Huang C, Pan X, Chen B. Comparative analysis of therapeutic effects of 3D and 2D laparoscopic radical gastrectomy for gastric cancer. Anhui Med J. 2018;39(9):1136–8.
21.
Yazawa H, Takiguchi K, Imaizumi K, Wada M, Ito F. Surgical outcomes of total laparoscopic hysterectomy with 2-dimensional versus 3-dimensional laparoscopic surgical systems. Fukushima J Med Sci. 2018;64(1):38–45.CrossRef
22.
Liang H, Liang W, Lei Z, Liu Z, Wang W, He J, et al. Three-dimensional versus two-dimensional video-assisted endoscopic surgery: a meta-analysis of clinical data. World J Surg. 2018;42(11):3658–68.CrossRef
23.
Tang FJ, Qi L, Jiang HC, Tong SY, Li Y. Comparison of the clinical effectiveness of 3D and 2D imaging systems for laparoscopic radical cystectomy with pelvic lymph node dissection. J Int Med Res. 2016;44(3):613–9.CrossRef
24.
Roberts KE, Bell RL, Duffy AJ. Evolution of surgical skills training. World J Gastroenterol. 2006;12(20):3219–24.CrossRef
25.
Noda H, Suminaga Y, Kato T, Kamiyama H, Konishi F. Laparoscopic adrenalectomy by general surgeons familiar with laparoscopic surgical skills: experiences of a single center. Asian J Endosc Surg. 2011;4(1):16–9.CrossRef
Metadata
Title
Two-dimensional versus three-dimensional laparoscopic gastrectomy in surgical efficacy for gastric cancer: a systematic review and meta-analysis
Authors
G. Zu
K. Jiang
T. Zhou
N. Che
X. Zhang
Publication date
01-01-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 1/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02116-9

Other articles of this Issue 1/2020

Clinical and Translational Oncology 1/2020 Go to the issue

Review Article

Overview on the role of preoperative therapy in the management of kidney cancer

Research Article

Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy

Research Article

MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis

Correspondence

Is it time to change follow-up recommendations in colorectal cancer?

Research Article

Unveiling the mechanisms of immune evasion in pancreatic cancer: may it be a systemic inflammation responsible for dismal survival?

Brief Research Article

Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits